Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Stryker Corp., solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Stryker Corp. debt to equity ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Stryker Corp. debt to capital ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Stryker Corp. debt to assets ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Stryker Corp. financial leverage ratio decreased from Q3 2021 to Q4 2021 but then increased from Q4 2021 to Q1 2022 not reaching Q3 2021 level. |
Debt to Equity
Stryker Corp., debt to equity calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Current maturities of debt | 214) | 7) | 22) | 6) | 15) | 761) | 1,119) | 1,110) | 1,103) | 859) | 526) | 539) | 521) | 1,373) | 1,275) | 1,277) | 1,984) | 632) | 632) | 774) | 35) | |||||||
| Long-term debt, excluding current maturities | 13,885) | 12,472) | 12,629) | 12,734) | 13,059) | 13,230) | 12,008) | 11,811) | 9,404) | 10,231) | 7,889) | 7,974) | 7,950) | 8,486) | 5,928) | 5,925) | 5,920) | 6,590) | 6,593) | 6,592) | 7,184) | |||||||
| Total debt | 14,099) | 12,479) | 12,651) | 12,740) | 13,074) | 13,991) | 13,127) | 12,921) | 10,507) | 11,090) | 8,415) | 8,513) | 8,471) | 9,859) | 7,203) | 7,202) | 7,904) | 7,222) | 7,225) | 7,366) | 7,219) | |||||||
| Total Stryker shareholders’ equity | 15,046) | 14,877) | 14,178) | 13,820) | 13,502) | 13,084) | 12,986) | 12,754) | 13,115) | 12,807) | 12,315) | 11,943) | 11,693) | 11,730) | 9,860) | 9,460) | 9,214) | 9,966) | 10,425) | 10,035) | 9,704) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to equity1 | 0.94 | 0.84 | 0.89 | 0.92 | 0.97 | 1.07 | 1.01 | 1.01 | 0.80 | 0.87 | 0.68 | 0.71 | 0.72 | 0.84 | 0.73 | 0.76 | 0.86 | 0.72 | 0.69 | 0.73 | 0.74 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 0.48 | 0.50 | 0.53 | 0.55 | 0.55 | 0.57 | 0.59 | 0.64 | 0.60 | 0.58 | 0.60 | 0.61 | 0.62 | — | — | — | — | — | — | — | — | |||||||
| Cigna Group | 0.72 | 0.71 | 0.72 | 0.68 | 0.66 | 0.65 | 0.75 | 0.77 | 0.81 | 0.83 | 0.87 | 0.89 | 0.95 | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 0.76 | 0.75 | 0.79 | 0.81 | 0.87 | 0.93 | 0.97 | 1.05 | 1.10 | 1.07 | 1.10 | 1.16 | 1.25 | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 0.65 | 0.64 | 0.64 | 0.66 | 0.69 | 0.60 | 0.61 | 0.62 | 0.68 | 0.63 | 0.65 | 0.63 | 0.64 | — | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 0.87 | 0.80 | 0.77 | 0.50 | 0.54 | 0.51 | 0.51 | 0.56 | 0.66 | 0.49 | 0.55 | 0.50 | 0.58 | — | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 0.50 | 0.51 | 0.60 | 0.60 | 0.57 | 0.49 | 0.49 | 0.51 | 0.52 | 0.51 | 0.50 | 0.50 | 0.50 | — | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 0.65 | 0.64 | 0.67 | 0.70 | 0.70 | 0.66 | 0.67 | 0.72 | 0.91 | 0.71 | 0.82 | 0.80 | 0.74 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Debt to equity = Total debt ÷ Total Stryker shareholders’ equity
= 14,099 ÷ 15,046 = 0.94
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Stryker Corp. debt to equity ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
Debt to Capital
Stryker Corp., debt to capital calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Current maturities of debt | 214) | 7) | 22) | 6) | 15) | 761) | 1,119) | 1,110) | 1,103) | 859) | 526) | 539) | 521) | 1,373) | 1,275) | 1,277) | 1,984) | 632) | 632) | 774) | 35) | |||||||
| Long-term debt, excluding current maturities | 13,885) | 12,472) | 12,629) | 12,734) | 13,059) | 13,230) | 12,008) | 11,811) | 9,404) | 10,231) | 7,889) | 7,974) | 7,950) | 8,486) | 5,928) | 5,925) | 5,920) | 6,590) | 6,593) | 6,592) | 7,184) | |||||||
| Total debt | 14,099) | 12,479) | 12,651) | 12,740) | 13,074) | 13,991) | 13,127) | 12,921) | 10,507) | 11,090) | 8,415) | 8,513) | 8,471) | 9,859) | 7,203) | 7,202) | 7,904) | 7,222) | 7,225) | 7,366) | 7,219) | |||||||
| Total Stryker shareholders’ equity | 15,046) | 14,877) | 14,178) | 13,820) | 13,502) | 13,084) | 12,986) | 12,754) | 13,115) | 12,807) | 12,315) | 11,943) | 11,693) | 11,730) | 9,860) | 9,460) | 9,214) | 9,966) | 10,425) | 10,035) | 9,704) | |||||||
| Total capital | 29,145) | 27,356) | 26,829) | 26,560) | 26,576) | 27,075) | 26,113) | 25,675) | 23,622) | 23,897) | 20,730) | 20,456) | 20,164) | 21,589) | 17,063) | 16,662) | 17,118) | 17,188) | 17,650) | 17,401) | 16,923) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to capital1 | 0.48 | 0.46 | 0.47 | 0.48 | 0.49 | 0.52 | 0.50 | 0.50 | 0.44 | 0.46 | 0.41 | 0.42 | 0.42 | 0.46 | 0.42 | 0.43 | 0.46 | 0.42 | 0.41 | 0.42 | 0.43 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 0.33 | 0.34 | 0.35 | 0.35 | 0.35 | 0.36 | 0.37 | 0.39 | 0.38 | 0.37 | 0.38 | 0.38 | 0.38 | — | — | — | — | — | — | — | — | |||||||
| Cigna Group | 0.42 | 0.42 | 0.42 | 0.40 | 0.40 | 0.40 | 0.43 | 0.44 | 0.45 | 0.45 | 0.46 | 0.47 | 0.49 | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 0.43 | 0.43 | 0.44 | 0.45 | 0.47 | 0.48 | 0.49 | 0.51 | 0.52 | 0.52 | 0.52 | 0.54 | 0.56 | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.38 | 0.38 | 0.38 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | — | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 0.46 | 0.44 | 0.43 | 0.33 | 0.35 | 0.34 | 0.34 | 0.36 | 0.40 | 0.33 | 0.35 | 0.33 | 0.37 | — | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 0.34 | 0.34 | 0.37 | 0.37 | 0.36 | 0.33 | 0.33 | 0.34 | 0.34 | 0.34 | 0.33 | 0.34 | 0.33 | — | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 0.39 | 0.39 | 0.40 | 0.41 | 0.41 | 0.40 | 0.40 | 0.42 | 0.48 | 0.41 | 0.45 | 0.44 | 0.43 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Debt to capital = Total debt ÷ Total capital
= 14,099 ÷ 29,145 = 0.48
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Stryker Corp. debt to capital ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
Debt to Assets
Stryker Corp., debt to assets calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Current maturities of debt | 214) | 7) | 22) | 6) | 15) | 761) | 1,119) | 1,110) | 1,103) | 859) | 526) | 539) | 521) | 1,373) | 1,275) | 1,277) | 1,984) | 632) | 632) | 774) | 35) | |||||||
| Long-term debt, excluding current maturities | 13,885) | 12,472) | 12,629) | 12,734) | 13,059) | 13,230) | 12,008) | 11,811) | 9,404) | 10,231) | 7,889) | 7,974) | 7,950) | 8,486) | 5,928) | 5,925) | 5,920) | 6,590) | 6,593) | 6,592) | 7,184) | |||||||
| Total debt | 14,099) | 12,479) | 12,651) | 12,740) | 13,074) | 13,991) | 13,127) | 12,921) | 10,507) | 11,090) | 8,415) | 8,513) | 8,471) | 9,859) | 7,203) | 7,202) | 7,904) | 7,222) | 7,225) | 7,366) | 7,219) | |||||||
| Total assets | 36,137) | 34,631) | 34,145) | 33,698) | 33,455) | 34,330) | 32,286) | 31,483) | 29,440) | 30,167) | 26,659) | 26,354) | 25,937) | 27,229) | 22,084) | 21,570) | 22,133) | 22,197) | 21,485) | 21,292) | 20,517) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Debt to assets1 | 0.39 | 0.36 | 0.37 | 0.38 | 0.39 | 0.41 | 0.41 | 0.41 | 0.36 | 0.37 | 0.32 | 0.32 | 0.33 | 0.36 | 0.33 | 0.33 | 0.36 | 0.33 | 0.34 | 0.35 | 0.35 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 0.23 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.27 | 0.29 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | — | — | — | — | — | — | — | — | |||||||
| Cigna Group | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 | 0.22 | 0.23 | 0.24 | 0.24 | 0.25 | 0.25 | 0.26 | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 0.24 | 0.24 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 | 0.30 | 0.31 | 0.31 | 0.31 | 0.33 | 0.34 | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 0.23 | 0.24 | 0.23 | 0.24 | 0.24 | 0.23 | 0.24 | 0.24 | 0.26 | 0.26 | 0.26 | 0.25 | 0.26 | — | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 0.29 | 0.29 | 0.28 | 0.19 | 0.20 | 0.20 | 0.21 | 0.21 | 0.23 | 0.20 | 0.22 | 0.21 | 0.22 | — | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 0.28 | 0.28 | 0.31 | 0.31 | 0.31 | 0.27 | 0.28 | 0.28 | 0.29 | 0.28 | 0.28 | 0.28 | 0.28 | — | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 0.21 | 0.22 | 0.22 | 0.23 | 0.23 | 0.22 | 0.23 | 0.24 | 0.27 | 0.23 | 0.26 | 0.25 | 0.24 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Debt to assets = Total debt ÷ Total assets
= 14,099 ÷ 36,137 = 0.39
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Stryker Corp. debt to assets ratio improved from Q3 2021 to Q4 2021 but then deteriorated significantly from Q4 2021 to Q1 2022. |
Financial Leverage
Stryker Corp., financial leverage calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Total assets | 36,137) | 34,631) | 34,145) | 33,698) | 33,455) | 34,330) | 32,286) | 31,483) | 29,440) | 30,167) | 26,659) | 26,354) | 25,937) | 27,229) | 22,084) | 21,570) | 22,133) | 22,197) | 21,485) | 21,292) | 20,517) | |||||||
| Total Stryker shareholders’ equity | 15,046) | 14,877) | 14,178) | 13,820) | 13,502) | 13,084) | 12,986) | 12,754) | 13,115) | 12,807) | 12,315) | 11,943) | 11,693) | 11,730) | 9,860) | 9,460) | 9,214) | 9,966) | 10,425) | 10,035) | 9,704) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||
| Financial leverage1 | 2.40 | 2.33 | 2.41 | 2.44 | 2.48 | 2.62 | 2.49 | 2.47 | 2.24 | 2.36 | 2.16 | 2.21 | 2.22 | 2.32 | 2.24 | 2.28 | 2.40 | 2.23 | 2.06 | 2.12 | 2.11 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | 2.09 | 2.10 | 2.14 | 2.17 | 2.17 | 2.21 | 2.20 | 2.25 | 2.21 | 2.18 | 2.15 | 2.16 | 2.19 | — | — | — | — | — | — | — | — | |||||||
| Cigna Group | 3.31 | 3.29 | 3.25 | 3.17 | 3.16 | 3.09 | 3.33 | 3.37 | 3.43 | 3.44 | 3.46 | 3.52 | 3.64 | — | — | — | — | — | — | — | — | |||||||
| CVS Health Corp. | 3.15 | 3.10 | 3.16 | 3.16 | 3.24 | 3.32 | 3.38 | 3.46 | 3.54 | 3.48 | 3.52 | 3.57 | 3.68 | — | — | — | — | — | — | — | — | |||||||
| Elevance Health Inc. | 2.79 | 2.70 | 2.74 | 2.75 | 2.83 | 2.61 | 2.55 | 2.55 | 2.60 | 2.44 | 2.48 | 2.46 | 2.48 | — | — | — | — | — | — | — | — | |||||||
| Humana Inc. | 3.02 | 2.76 | 2.79 | 2.56 | 2.64 | 2.55 | 2.44 | 2.67 | 2.80 | 2.42 | 2.52 | 2.44 | 2.61 | — | — | — | — | — | — | — | — | |||||||
| Intuitive Surgical Inc. | 1.13 | 1.14 | 1.13 | 1.13 | 1.14 | 1.15 | 1.15 | 1.16 | 1.16 | 1.18 | 1.18 | 1.17 | 1.17 | — | — | — | — | — | — | — | — | |||||||
| Medtronic PLC | 1.78 | 1.81 | 1.92 | 1.91 | 1.87 | 1.79 | 1.79 | 1.80 | 1.81 | 1.79 | 1.78 | 1.78 | 1.79 | — | — | — | — | — | — | — | — | |||||||
| UnitedHealth Group Inc. | 3.04 | 2.96 | 3.03 | 3.05 | 3.09 | 3.01 | 2.93 | 3.03 | 3.32 | 3.02 | 3.16 | 3.15 | 3.12 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Financial leverage = Total assets ÷ Total Stryker shareholders’ equity
= 36,137 ÷ 15,046 = 2.40
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Stryker Corp. financial leverage ratio decreased from Q3 2021 to Q4 2021 but then increased from Q4 2021 to Q1 2022 not reaching Q3 2021 level. |